The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline Patient-Reported Outcomes

MLA

Hélène Sapin, et al. “The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline Patient-Reported Outcomes.” Diabetes Therapy, vol. 11, Sept. 2020, pp. 2383–99. EBSCOhost, https://doi.org/10.1007/s13300-020-00908-9.

APA

Hélène Sapin, Marco Orsini Federici, E. Heitmann, U. Aigner, Luis-Emilio Garcia-Perez, Myriam Rosilio, Kristina S. Boye, Kirsi Norrbacka, Francesco Giorgino, Heike Jung, & Bruno Guerci. (2020). The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline Patient-Reported Outcomes. Diabetes Therapy, 11, 2383–2399. https://doi.org/10.1007/s13300-020-00908-9

Chicago

Hélène Sapin, Marco Orsini Federici, E. Heitmann, U. Aigner, Luis-Emilio Garcia-Perez, Myriam Rosilio, Kristina S. Boye, et al. 2020. “The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline Patient-Reported Outcomes.” Diabetes Therapy 11 (September): 2383–99. doi:10.1007/s13300-020-00908-9.